

Which patients might benefit the most from isatuximab-based combinations in the relapsed setting?
Oct 2, 2022
Roman Hájek, from the University of Ostrava, discusses the benefits of isatuximab-based combinations in treating relapsed multiple myeloma patients refractory to lenalidomide-based therapy. The focus is on the efficacy of isatuximab with carfilzomib and dexamethasone, highlighting the role of immunomodulatory agents in improving outcomes.
Chapters
Transcript
Episode notes